Development of a liposome formulation of ethambutol.
A liposomal formulation capable of encapsulating 76 to 92% of the antimycobacterial drug ethambutol and showing prolonged in vitro release kinetics is described. In vitro efficacy is equivalent to that of the free drug, suggesting that encapsulation of ethambutol has the potential to shorten the current regimens for tuberculosis.
Wiens
Theresa
T
Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada V5Z 3J5.
Redelmeier
Thomas
T
Av-Gay
Yossef
Y
D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000494:pharmacology; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004977:Ethambutol / Q000008:administration & dosage* / Q000494:pharmacology; D008081:Liposomes; D008826:Microbial Sensitivity Tests; D009163:Mycobacterium bovis / Q000187:drug effects; D012995:Solubility
D000995:Antitubercular Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D008081:Liposomes; D004977:Ethambutol